Research chemical preclinical only
BPC-157 demonstrates a distinctive modulatory effect on nitric oxide levels, increasing or decreasing NO production as needed to maintain vascular homeostasis, always combined with counteraction of free radical formation
A GP or specialist can assess whether an individual's medical history, current medications, or underlying conditions make the use of a GLP-1/GIP/glucagon receptor agonist particularly risky
For the treatment of colitis, ischemia and reperfusion in rats, BPC 157 quickly restores blood supply to the chemically injured area and counteracts worsening effects induced by L-NAME or L-arginine
BPC-157 complements these effects through its enhancement of cellular proliferation and migrationincreasing fibroblast numbers at sites requiring matrix deposition while simultaneously upregulating MMP-2 by 85% to facilitate cellular movement through dense matrix environments, then stimulating TIMP production to prevent excessive proteolysis
